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Metastatic triple-negative breast cancer
Transcriptomics
A B S T R A C T
The intrinsic characteristics of the tumor microenvironment (TME), including acidic pH and overexpression of
hydrolytic enzymes, offer an exciting opportunity for the rational design of TME-drug delivery systems (DDS).
We developed and characterized a pH-responsive biodegradable poly-L-glutamic acid (PGA)-based combination
conjugate family with the aim of optimizing anticancer effects. We obtained combination conjugates bearing
Doxorubicin (Dox) and aminoglutethimide (AGM) with two Dox loadings and two different hydrazone pH-
sensitive linkers that promote the specific release of Dox from the polymeric backbone within the TME. Low Dox
loading coupled with a short hydrazone linker yielded optimal effects on primary tumor growth, lung metastasis
(∼90% reduction), and toxicological profile in a preclinical metastatic triple-negative breast cancer (TNBC)
murine model. The use of transcriptomic analysis helped us to identify the molecular mechanisms responsible for
such results including a differential immunomodulation and cell death pathways among the conjugates. This
data highlights the advantages of targeting the TME, the therapeutic value of polymer-based combination ap-
proaches, and the utility of –omics-based analysis to accelerate anticancer DDS.
1. Introduction
The hypoxic and acidic environment of the tumor microenviron-
ment (TME) promotes the survival of cancer cells over normal cells [1]
and represents a crucial target for the newest generation of anticancer
drug delivery systems (DDS). The higher glycolytic rate of tumor cells
generates and sustains the acidic character of the TME [2] and provides
a rationale for the specific design of targeted DDS. If properly en-
gineered, nanoscale therapeutics passively accumulate within the TME
of adequately vascularize tumors [3–5] by the enhanced permeability
and retention (EPR) effect and the presence of pH-labile linkers within
the DDS can trigger conjugated drug release. Other than TME-targeting
of pH-labile DDS, endocytic internalization promotes lysosomal de-
gradation [6] of polymers such as poly-L-glutamatic acid (PGA), thanks
to the presence of hydrolytic enzymes such as Cathepsin B [7] as well as
an acidic pH.
Our laboratory recently reported the development of PGA-based
combination conjugates bearing a synergistic ratio of the anthracycline
drug doxorubicin (Dox) and the aromatase inhibitor
Aminoglutethimide (AGM) [8]. Specific engineering of the three-di-
mensional (3D) conformation permitted similar optimal release rates
for Dox and AGM, with release rate representing the parameter con-
trolling drug-drug synergism [8,9], translating to enhanced antitumor
efficacy in an orthotopic 4T1 triple negative breast cancer (TNBC)
preclinical model [10]. The release of both drugs via protease-cleavable
drug linkers relied on the heterogeneous expression of various hydro-
lytic enzymes within the TME activity (at both the patient [11] and
tumor level [12]). This fact highlights the need for patient stratification
in DDS treatment cohorts, a requirement exemplified by clinical data
obtained for Opaxio®, which displayed optimal activity in phase III
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clinical trials in premenopausal women with optimally high levels of
estrogen to promote cathepsin B activity [13].
We aimed to potentiate the therapeutic capacity of our previously
described PGA-combination conjugates by further promoting metastasis
inhibition through the incorporation of a pH-labile linker for Dox
(simple hydrazone moiety or complex EMCH [N-ε-maleimidocaproic
acid hydrazide] moiety), while retaining the optimized glycine-based
linking chemistry for AGM [8], using our metastatic TNBC mice as
preclinical model [10] Of note, TME-targeting represents a promising
alternative means to inhibit metastasis in TNBC, a particularly ag-
gressive breast cancer subtype that features a unique microenvironment
distinct from that of other subtypes, especially when compared to Lu-
minal A [14,15]. Furthermore, as a consequence of molecular com-
plexity and heterogeneity, TNBC lacks the targeted treatments available
for other subtypes.
During this study, we discovered that low Dox loading and shorter
hydrazone linkers yielded optimal antitumor and antimetastatic effects
in our TNBC model. RNA sequencing (RNA-seq) analysis employed to
explore the mechanism of action of TME-targeted conjugates revealed
the inhibition of metastatic pathways and the importance of im-
munomodulation. This powerful genomics tool allowed us to elucidate
the functional aspects of gene expression driving cell death at the
genome-wide level and the establishment of relationships with the
physico-chemical descriptors. As far as our knowledge, this is one of the
few experimental analysis of this type within Polymer Therapeutics and
demonstrates the enormous potential of polymer genomics [16] to
elucidate the molecular mechanism of action and identify promising
molecular targets.
2. Materials and methods
Detailed materials and ethical statements can be found in
Supplementary Information (SI).
2.1. Synthesis of polymer-drug conjugates
2.1.1. Synthesis of single conjugates
Detailed synthetic procedure for single conjugates can be found in
Supplementary Information (SI).
2.1.2. Synthesis of combination conjugates
2.1.2.1. Synthesis of PGA-(G-AGM)-Hyd-Dox. We employed an
optimized protocol derived from a previously described strategy by
Van Heeswijk in order to generate PGA-Hyd-Dox conjugates [17].
Hydrazone-based combination conjugates were synthesized by one-pot
direct attachment of G-AGM and tert-butyl-carbazate. Further Boc
deprotection of the amino-group allowed final Dox coupling. PGA
(300mg, 2.32mmol, 1.0 eq., 100 units, Mw ∼13 KDa) was dissolved in
10mL of anhydrous DMF in an inert atmosphere. DMTMM.BF4 (0.3 eq.)
was added to the solution and 15min later G-AGM (0.164mmol,
58.2 mg) and tert-butyl-carbazate (18.38 mg, 0.139mmol, 0.06 eq. for
5% modification) were added. The reaction proceeded for 48 h and the
workup was performed as already described for PGAeNHeNHBoc (see
SI). Once the stability of G-AGM in TFA was ensured (Fig. SI5), Boc
release was performed as for the synthesis of PGAeNHeNH2 (see SI)
and Dox was coupled through a hydrazone bond following the same
procedure as for the synthesis of PGA-hyd-Dox (see SI).
2.1.2.2. Synthesis of PGA-(G-AGM)-EMCH-Dox. EMCH-Dox-based
combination conjugates were synthesized by one-pot direct
attachment of G-AGM and PD and further EMCH-Dox [18, 19]
coupling through the reduction of PD. PGA (300mg, 2.32mmol, 1.0
eq., 100 units, Mw∼13 KDa) was dissolved in 10mL of anhydrous DMF
in an inert atmosphere. DMTMM.BF4 (i.e. 15.34mg, 0.116mmol, 0.05
eq. for 5% modification) was added to the solution and 15min later G-
AGM (0.164mmol, 58.2mg) and PD (30.9 mg, 0.139mmol, 0.06 eq. for
5% modification) were added. The reaction proceeded for 48 h and the
workup was performed as for the PGAeNHeNHBoc. An aliquot was
isolated for G-AGM and PD loading determination. For EMCH-Dox
attachment, PGA-(G-AGM)-PD was dissolved in anhydrous DMF and
EMCH-Dox (750.76 g/mol, 1.5 eq. with respect to PD modification) was
dissolved and TCEP (0.15 eq. with respect to the PD modification) was
finally added as reducing agent. Boc release was performed as for the
synthesis of PGAeNHeNH2 (see SI) and Dox was coupled through a
hydrazone bond following the same procedure as for the synthesis of
PGA-hyd-Dox (see SI).
To note, detailed Physico-chemical Characterization protocols can
be found in SI.
2.2. Cell culture and In vitro cytotoxicity analysis of conjugate
The 4T1 cell line was maintained in RPMI supplemented with 10%
heat inactivated FBS at 37 °C in a controlled atmosphere of air/CO2
(95/5 vol/vol). Media was replaced every 48–72 h and underwent
passaging when 80% cell confluence was reached. Cytotoxic assays
were performed according to a previously described protocol [8]. In
brief, cells were seeded in sterile 96-well microtiter plates at a con-
centration of 6250 cells/cm2. Further details can be found in SI.
2.3. Drug release kinetics
2.3.1. pH-dependent drug release
Specific Dox release under mild acidic conditions was demonstrated
in vitro by liquid-liquid extraction and further quantification by re-
versed-phase high-performance liquid chromatography (RP-HPLC). The
conjugates were incubated in 50mM PBS at pH 7.4 and pH 5.0, mi-
micking the blood and tumor (and/or lysosomal) environment respec-
tively. See SI for detailed information.
2.3.2. Cathepsin B-dependent drug release kinetics
Cathepsin B (5 U) was added to a solution of 2mg of each conjugate,
in 1mL of a pH 6 buffer composed of 20mM sodium acetate, 2 mM
ethylenediaminetetraacetic acid (EDTA), and 5mM dithiothreitol
(DTT). The incubation was carried out at 37 °C. Aliquots (100 μl) were
taken at times up to 48 h, immediately frozen in liquid nitrogen, and
stored in the dark until assayed by HPLC as described above for pH-
dependent drug release assay. The free drug (0.75mgmL−1) was also
incubated under the same conditions and later used as the reference
control.
2.4. Evaluation of in vivo antitumor activity and safety of conjugates
2.4.1. Establishment of highly metastatic 4T1 murine breast cancer model
and in vivo validation of conjugates
The spontaneously metastatic TNBC model was developed as pre-
viously reported [8,10]. See SI for further information.
2.4.2. In vivo study at 10 mg/kg dox-equivalent dose
Eight days before induction, tumor sizes reached 0.1 cm3 and mice
were split into representative groups. Conjugate-based treatments were
dissolved in sterile PBS and immediately injected intravenously (i.v.) in
four doses of 10mg/kg of Dox equivalents every three days (See
Figs. 4A and SI).
2.4.3. Hematological study
Blood was extracted immediately after sacrificing mice by cardiac
puncture with a 1.0 mL heparinized syringe and transferred to a 2mL
Eppendorf tube. Blood was gently homogenized and left to reach RT
and then kept at 4 °C until analysis (within the first 30min after ex-
traction). Serum was isolated by centrifugation (4000 rpm, 10min,
4 °C) and analyzed using an automated hematologic analyzer (Sysmex
XT-2000i).
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2.4.4. Histopathological study
All tissues were washed in fresh PBS, carefully dried, weighed, and
fixed in paraformaldehyde (PFA) at room temperature for 24 h. PFA
was eliminated by successive washing with PBS (5 times× 20min,
rapid agitation). Once washed, tissues were stored in a solution of PBS
with 0.05% of sodium azide as preservant at 4 °C protected from light.
Further conventional Hematoxylin-Eosin staining was carried out (see
SI for further details).
2.4.5. Safety evaluation of treatments
Treatments safety was evaluated by tracking body weight and
comparisons with control and healthy animals, as well as further his-
topathological studies of key organs. The mice under study were ex-
amined daily in the search for any pain-related behavior or conduct
modification. Postmortem, major organs were also analyzed histo-
pathologically for any treatment-derived damage.
2.4.6. Tumor density
Tumor density was obtained by simple arithmetic calculation and
allowed us to elucidate differential stromal arrangement due to the
different treatments.
2.5. Evaluation of the antimetastatic effect of conjugates in the lung
Lung metastasis was evaluated following a previously described
protocol [20] with several improvements. See SI for a detailed protocol.
2.6. Transcriptomic study
2.6.1. Extraction of RNA from frozen tumors and sequencing
Total RNA isolation was performed from 50mg of previously pul-
verized frozen tumor employing the PureLink RNA Mini kit (Ambion-
Life Technologies) following manufacturer's recommendations. The On-
column PureLink DNase Kit (Invitrogen) was used to purify the DNA-
free RNA. The qualification and integrity of total RNA was performed
with an Agilent Technologies 2100 Bioanalyzer (or 4200 Tape Station).
TruSeq Stranded mRNA libraries were constructed and sequenced at
Macrogen (Seoul, Korea) using an Illumina HiSeq4000 platform
(paired-end with a length of 100 bp).
2.6.2. Mapping and quantification
Raw paired-end sequences were mapped against the mouse re-
ference genome with STAR aligner software [21]. There was no need to
trim or filter due to the high quality of the samples, checked with the
FastQC tool (URL: https://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). The mapping step was completed with a mean of
an 88% of uniquely mapped reads. The quantification of the transcripts
was performed with RSEM software [22].
2.6.3. RNA-seq data analysis
Low count genes in RNA-seq count data were filtered with NOISeq
package [23] and kept for the statistical analysis the 14,323 genes
having an average of more than one read count per million reads in any
of the four experimental groups. The resulting count matrix was nor-
malized by the sequencing depth to make samples comparable. Data
were transformed with the Voom approach [24] to get a normal dis-
tribution. The limma R package [25], which is based on linear models,
was used to obtain the differentially expressed genes among experi-
mental groups. Further information on the different comparison es-
tablished can be found in SI.
2.6.4. Functional analysis
Gene Ontology functional enrichment analysis using the Fisher's
exact test was performed for genes selected (nominal p-value<0.01) at
each of the above comparisons. Additionally, the log2-fold change at
each pair wise comparison was calculated and exported to PaintOmics 3
[26,27] for KEGG pathway analysis. KEGG pathways were manually
edited to improve interpretation of functional analysis results.
3. Results and discussion
3.1. Synthesis and characterization of polymer-drug conjugates
We previously demonstrated optimal therapeutic benefit with PGA-
AGM-Dox combination conjugates presenting a differential (faster) Dox
release rate when compared to AGM in an orthotopic TNBC model [10].
To further enhance this effect, we incorporated hydrazone-based pH-
sensitive linkers for Dox conjugation while retaining the original opti-
mized linking chemistry for AGM (Gly-AGM).
As shown in Figs. 1A and SI1, we employed two different pH-sen-
sitive hydrazone linkers: we used the direct conjugation through the C-
Fig. 1. Synthetic scheme followed to achieve for Poly-L-glutamate (PGA)-based combination conjugates. i. a) DMTMM.BF4, DIEA, anh-DMF, 15min, R.T. i. b)
t-butyl carbazate, G-AGM, 24 h, pH=8, R.T.; ii) TFA, 30min, R.T.; iii. a) DOX.HCL, CH3COOH (cat.), 36 h. iii. b) NaHCO3 (dil) iv. a) DMTMM.BF4, DIEA, anh-DMF,
15min, R.T. iv. b) Pyridyldithiol, G-AGM, 24 h, pH=8, R.T.; v. a) EMCH-Dox, TCEP (cat.); v. b) NaHCO3 (dil).
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13 Dox ketone [17] or conjugation employing a flexible, hydrophobic,
and longer maleimido linker (EMCH) that we hypothesized would
provide even faster Dox release [18]. Direct conjugation required the
previous modification of the PGA backbone with tert-butylcarbazate.
The EMCH spacer required the previous modification of Dox to obtain
EMCH-Dox [19] as well as previous modification of the PGA backbone
with a PD moiety. The last stage involved the reduction of the disulfide
bond to yield the conjugate through the thioether derivative (Figs. 1A
and SI1). This Dox-linker strategy has its origin in the development of
Aldoxorubicin (formerly, INNO-206, EMCH-Dox) as a bovine serum
albumin (BSA)-binding-Dox prodrug [28] and has been reported pre-
viously for a PGA-based combination conjugate [29].
Additionally, to explore the effect of different Dox loadings and
encouraged by preliminary results demonstrating enhanced cytotoxi-
city in the lower Dox loading range [8], we fixed G-AGM content in all
combination conjugates at 10% mol, but varied Dox loading from 1%
mol (Low Loading [LL]) to 3% mol (High Loading [HL]) (Fig. 1C).
Unfortunately, we could not generate the single conjugate in-
corporating a high loading of the bulky EMCH moiety (PGA-EMCHHL),
probably due to steric impediments. We performed the direct attach-
ment of G-AGM and the precursor moieties (tert-butylcarbazate and
PD) by carbodiimide coupling to achieve our combination (Fig. 1A) and
single conjugates (Fig. SI1).
We then carried out physico-chemical characterization of all syn-
thesized conjugates (see SI). Fig. 2B depicts the spectra of re-
presentative conjugates with chemical shifts attributed to the in-
corporation of one or both drugs. The signal corresponding to the
ethylene group (δ 0.75 ppm) and those at the aromatic region (δ
7.5 ppm) indicated the presence of G-AGM. Dox aromatic rings signals
appeared in the region of δ 7.0–8.0 ppm and the methylene group of the
amino-sugar moiety at δ 1.25 ppm. The conjugates bearing EMCH-Dox,
presented a characteristic ethylene signal of the EMCH spacer (δ
3.3 ppm) also present in the combination conjugate; however, the
aromatic signals of the drug practically disappeared. Additionally, the
broadening of polymer signals also represented a sign of polymer
conjugation.
We also employed 1H NMR to evaluate single conjugates precursors,
PGA-PD, PGAeNHeNHBoc, PGAeNHeNH2, and the combination
conjugates precursors PGA-(G-AGM)-PD, PGA-(G-AGM)eNH-NHBoc,
and PGA-(G-AGM)eNHeNH2 (Figs. SI3 and SI4). Additional 1H NMR
assignments of final conjugates (Fig. SI12) can be compared with the
corresponding spectra of the free parent drugs, demonstrating the
presence of the drug within the nanoconjugate structure (Fig. SI11).
SEC elugrams demonstrated single homogeneous Mw distribution
by refractive index (RI), and no evidence of free drug presence (Fig. 2D
and E). We note that the conjugation of one or both drugs did not
significantly modify the Dh in solution by DLS (number) and most of the
conjugates exhibited a monomodal averaged Dh of ∼3–6 nm, except in
the case of the single conjugate PGA-(Hyd-Dox)LL (Dh ∼290 nm) and
the combination conjugate PGA-(G-AGM)-(EMCH-Dox)LL (Dh ∼18 nm).
Interestingly, DLS measurements in terms of intensity (Fig. SI13), re-
vealed a bimodal population distribution indicating the coexistence of
unimers and aggregates. Although we expected the higher Dox-loaded
conjugates and those bearing the hydrophobic EMCH linker to mark-
edly aggregate given the overall increased hydrophobicity, we actually
observed greater aggregation behavior for those with the lowest Dox
content. This counterintuitive finding may indicate that the overall
aqueous solution conformation is driven by a complex interplay of
dynamic factors (including the polyelectrolyte effect [30,31]) and not
only imposed by the hydrophobicity of the loaded drugs as a single
factor [8]. We aim to undertake additional studies involving com-
plementary techniques, such as in-flow fractionation techniques
[30,32] to reveal the contribution of both, hydrophobicity and poly-
electrolyte effect to the global spatial arrangement of conjugated
macromolecules.
3.2. Dox release kinetics as a crucial feature driving in vitro output
To understand the biological implications of different drug linker
use and drug loading/ratio in our conjugates, we performed cell toxicity
assays in 4T1 murine breast cancer cells. Fig. 3A depicts the in vitro
effect of the PGA-(G-AGM)-(Hyd-Dox)HL, PGA-(G-AGM)-(Hyd-Dox)LL,
PGA-(G-AGM)-(EMCH-Dox)HL, and PGA-(G-AGM)-(EMCH-Dox)LL com-
bination conjugates. Cell viability assays demonstrated higher cyto-
toxicity for the PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-
Dox)HL, and PGA-(G-AGM)-(EMCH-Dox)LL combination conjugates
when compared with PGA-(G-AGM)-(EMCH-Dox)HL, which displayed
very low cytotoxicity (Fig. 3A). Although cytotoxicity assays provided
non-statistically-significant differences at the range of concentrations
tested, both combination conjugates incorporating low Dox loadings
presented with trends towards higher cytotoxicity (IC50= 0.13 μg/mL
and 0.45 μg/mL for PGA-(G-AGM)-(EMCH-Dox)LL and PGA-(G-AGM)-
(Hyd-Dox)LL, respectively, vs. IC50= 0.79 μg/mL for PGA-(G-AGM)-
(Hyd-Dox)HL) (Fig. 3B). In contrast with our previously reported PGA-
(G-AGM)-Dox family [8], we did not observe any significant differences
in cell toxicity between the single and the combination conjugates (Fig.
SI15), indicating a lack of AGM:Dox synergism at the drug ratios pre-
sent upon hydrazone-mediated conjugation.
To explain this biological/therapeutic output, we evaluated Dox
release from the combination conjugates at physiological and acidic pH
as well as in the presence of Cathepsin B (Figs. 3C and SI16) and, as
expected, we found differential release profiles depending on Dox
loading and linker length. For the EMCH-derivatives, the PGA-(G-
AGM)-(EMCH-Dox)LL combination conjugate displayed rapid Dox re-
lease at pH 5.0 during the first 8 h, reaching a maximum of 16%, and a
slower Dox release (∼2%) at physiological pH (7.4). Remarkably, the
corresponding combination conjugate with higher Dox loading, PGA-
(G-AGM)-(EMCH-Dox)HL, displayed almost no Dox release at pH 5 or
7.4 (< 1%) during the same time period (Fig. SI16A-B). These results,
together with DLS measurements (by number) (Fig. 2C), suggest a
distinct conjugate solution conformation, due to a different spatial ar-
rangement of Dox molecules as a function of loading. We hypothesize
that high loading of EMCH-Dox promotes a more condensed structure
(lower Dh), with the hydrazone bond hidden from the acidic environ-
ment and thereby hindering Dox release. This may also explain the
difficulty we faced when attempting to increase Dox loading. Therefore,
we also hypothesize that low loadings of EMCH-Dox correlate with a
more swollen structure (higher Dh), promoting a higher level of hy-
drazone exposure and Dox release.
Conjugates obtained by direct conjugation displayed similar Dox
loading-related release behavior (Figs. 3C and SI16C). The PGA-(G-
AGM)-(Hyd-Dox)LL combination conjugate exhibited up to 10% Dox
released at pH 5.0 within 8 h and less than 1% at pH 7.4. In contrast, the
PGA-(G-AGM)-(Hyd-Dox)HL combination conjugate displayed only 2%
Dox release at pH 5.0 within the same time frame. Independently of the
Dox linking chemistry employed, lower loading correlated higher re-
lease rates, thereby explaining the differential cytotoxicity observed.
For hydrazone-derivative conjugates, we did not find any differences by
DLS in terms of number. However, measurement by intensity suggested
a higher aggregation tendency (larger Dh) for the combination con-
jugate bearing the lower Dox loading (PGA-(G-AGM)-(Hyd-Dox)LL
when compared to the corresponding conjugate with higher Dox
loading (PGA-(G-AGM)-(Hyd-Dox)HL (Figs. 2C and SI13).
As we conjugated AGM through a pH-stable chemical bond, we
expect AGM release from the PGA mainchain by cathepsin B-driven
degradation [8]. Therefore, we expected much faster overall Dox re-
lease rates from Dox-hydrazone-bearing conjugates than AGM release
(only influenced by protease presence). However, cathepsin B de-
gradation studies with (PGA-(G-AGM)-(Hyd-Dox)HL (Fig. SI16C) clearly
show that this assumption was wrong and that the final conjugate so-
lution conformation again was critical. The greater AGM bioavailability
vs. Dox obtained for this conjugate could be responsible for the lack of
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activity as well as drug synergism discovered. In the case of the most
active conjugate, (PGA-(G-AGM)-(Hyd-Dox)LL (Fig. 3C), same results
were seen, however in this particular case, and we believe is the reason
for the enhanced activity, Dox release profile was faster at very early
time-points (at pH 5 as well as in presence of cathepsin B, showing the
preferential hydrolytic mechanism triggering Dox release). Also, the
final relative release profile comparing Dox vs AGM could explain the
absence of drug synergism as an inverse relative bioavailable AGM:Dox
ratio from that previously identified as synergistic [8] was obtained.
In summary, the release kinetics findings fully correlate with in vitro
results: the combination conjugate displaying the highest IC50 (PGA-(G-
AGM)-(EMCH-Dox)HL) demonstrated almost no Dox release, while the
conjugate showing the highest Dox release (PGA-(G-AGM)-(EMCH-
Dox)LL) corresponded to the highest cytotoxicity. As demonstrated
previously [8,33], the selection of drug linkers, drug ratios, and drug
loadings in a polymer-drug combination conjugate can drastically
modify the entire macromolecular configuration, varying key para-
meters, including hydrodynamic size and drug release kinetics, that
directly influence biological readout.
3.3. Study of combination conjugates antitumor activity and safety in a
spontaneously metastatic TNBC murine model
The antitumor/antimetastatic effect of polymer-drug combination
conjugates requires accumulation within the tumor site by passive (EPR
effect) accumulation and/or active targeting. We and others have pre-
viously described the spontaneously metastatic 4T1 TNBC murine
model developed in immunocompetent BALB/c mice [10,34,35], which
included the study of EPR effect [4]. This preclinical model faithfully
mimics the human clinical scenario, offering an opportunity for reliable
Fig. 2. Physicochemical characterization of PGA-based combination conjugates. A) Physico-chemical characteristics of PGA-drug conjugates. B) Representative
1H NMR spectra (D2O, 300MHz). C) Size distribution graphs in number obtained by DLS in PBS at 5.0 mgmL−1. D) and E) SEC chromatograms for parental PGA
compared with single conjugates and combination conjugates, respectively (RI detection, peak at 17.1 corresponds to the counter-cation Na+).
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DDS in vivo testing [10].
To examine combination conjugate antitumor efficacy, we ran-
domly distributed tumor-bearing mice whose volumes had reached
∼0.1 cm3 (maximal EPR effect [10]) into representative groups and
scheduled four treatments every three days with the conjugates
showing the best cytotoxic activity (at 10mg/kg Dox equivalents)
(Fig. 4A). In addition, we administered Dox to a control group at 5mg/
kg and unconjugated PGA as a vehicle control at 25mg/kg (maximum
concentration used for the conjugates as carrier). Both PGA-(G-AGM)-
(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL combination conjugates
exhibited substantial antitumor activity (50% tumor reduction com-
pared with PBS-treated mice) (Fig. 4B). Furthermore, we noted a si-
milar decrease in tumor volume in the free Dox-treated animals.
However, treatment with unconjugated PGA and PGA-(G-AGM)-(Hyd-
Dox)HL did not significantly diminish tumor growth when compared
with PBS-treated mice. In good agreement with our in vitro findings we
did not find improvement on efficacy when we administered the phy-
sical mixture of single conjugates (PGA-(G-AGM) + PGA-(Hyd-Dox)LL)
Fig. 3. Cell viability and kinetics of drug release studies for combination conjugates. A) Cell viability measured by MTS assay after 72 h of treatment with PGA-
(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-Dox)HL, PGA-(G-AGM)-(EMCH-Dox)L, PGA-(G-AGM)-(Hyd-Dox)HL or free Dox. Data expressed as mean ± SEM, at least
n= 3 experiments per treatment. B) Determination of IC50 for the free Dox and the polymer-drug conjugates in mouse 4T1 breast cancer cell line. C) Kinetics of drug
(s) release from PGA-(G-AGM)-(Hyd-Dox)LL under hydrolytic as well as proteolytic (cathepsin B) conditions; n=3 experiments per assay.
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or the combination conjugate PGA-(G-AGM)-(Hyd-Dox)LL in compar-
ison to the administration of the PGA-(Hyd-Dox)LL single conjugate,
suggesting, in this case, that the presence of AGM does play a relatively
minor role (Fig. SI14). As stated above, this result could be explained by
the differential bioavailable drug ratio achieved when compared to
previous protease labile PGA-AGM-Dox conjugates [8] (Figs. 3C and
SI16). Dox concentration in the tumor site is significantly higher at
early time points and more importantly, it relies on a hydrolytic trigger,
Fig. 4. In vivo antitumor and safety evaluation of combination conjugates in an orthotopic TNBC mice model. A) Routine of treatment administration. The
treatment started at the previously determined Max EPR point. B) Tumor growth inhibition of previously selected polymer-drug conjugates. Data represents
mean ± SEM. Statistical significance was determined using an ANOVA t-test, (*p < 0.05, **p < 0.01, ***p < 0.001). C) Mice weight loss along treatments D)
Comparison of tumor density with different treatments at the experimental endpoint. E) Comparison of H&E and Ki-67 axial sections of tumors at experimental
endpoint after different treatments. F) Mice-treated heart sections showing Dox-induced cardiotoxicity by means of H&E and Masson's immunostaining compared
with the cardio-safety displayed by the combination conjugates. G) Kaplan-Meyer survival curves demonstrating safety of the combination conjugates with the
exception of PGA-(G-AGM)-(EMCH-Dox)LL, that shows only 50% of mice survival. H) Relative liver weight by treatments demonstrating tumor-related hepatomegaly
in the PBS group, that was partially improved with Dox, PGA-(G-AGM)-(Hyd-Dox)HL, PGA-(G-AGM)-(Hyd-Dox)LL and greater organ weight related to the treatment
PGA-(G-AGM)-(EMCH-Dox)LL. . Statistical significance was determined using an ANOVA t-test (*p < 0.05, **p < 0.01, ***p < 0.001).
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therefore, we would expect Dox released already in the tumor stroma,
but not AGM (Fig. 3C).
To further understand the effect of our combination conjugates on
tumor growth, we studied tumor density (Fig. 4C) and the relationship
between proliferation (via Ki-67 immunostaining of axial sections) and
tumor necrosis (Fig. 4D) at the experimental endpoint. We did not see
significant tumor necrosis within the free Dox treated animals, perhaps
due to lower levels of persistence within the tumor stroma (Fig. 4D).
However, treatment with the two combination conjugates displaying
the most promising therapeutic effects (PGA-(G-AGM)-(Hyd-Dox)LL and
PGA-(G-AGM)-(EMCH-Dox)LL) led to the appearance of large necrotic
tumor cores (Fig. 4D) and optimal tumor growth inhibition (Fig. 4B).
Furthermore, these two combination conjugates inhibited the pro-
liferation of outer viable cells (Fig. 4D), indicating possible cell-cycle
arrest induced by prolonged Dox exposure driven by both passive
conjugate accumulation and sustained stromal release [36,37]. Al-
though necrosis is typically related with hypodense tissue regions, our
analyses demonstrated higher necrosis in the denser tumors (∼1.9 g/
cm3 vs. Placebo ∼1.4 g/cm3) (Fig. 4D). PGA-(G-AGM)-(Hyd-Dox)HL
treated tumors presented the lowest density, similar to the PBS control
group (∼1.3 g/cm3) (Fig. 4D). Of note, 4T1 tumors develop coagulative
necrosis [38,39] characterized by the preservation of the basic struc-
tural outline of the affected cells in a compact network and the accu-
mulation of inflammatory cells [40]. Dox-related hypoxia [41] may
lead to tumor tissue ischemia and thus to more hypoxic tumors re-
sulting in increased coagulative necrosis and therefore, denser tumors.
Additionally, we found evidence of calcification in the core of the
densest tumors (PGA-(G-AGM)-(EMCH-Dox)LL), which corresponds to
the rapid fast development of necrosis, in response to a highly effective
antitumor treatment. Such calcification could drastically increase
tumor weight and, therefore, tumor density.
To assess safety, we systematically evaluated, body weight, general
aspect, behavior, and post-mortem major organ weights of all animals
employed. We observed no significant alterations in body weight of
animals treated with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-
Dox)HL, or Dox, which displayed a 100% survival rate (Fig. 4E and F).
However, PGA-(G-AGM)-(EMCH-Dox)LL treated presented with le-
thargy, weakness, and slight dyspnea immediately following the third
and fourth iv. Administrations, with only 50% of animals surviving
(Fig. 4F). Post-mortem organ analysis revealed increased relative liver
weight in all animals compared to healthy (non-tumor bearing animals)
noting the largest relative liver weight increase in animals treated with
PGA-(G-AGM)-(EMCH-Dox)LL (Fig. 4G). However, we note that animals
treated with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-Dox)HL,
and Dox exhibited smaller increases in relative liver weight when
compared to the PBS-treated (tumor-bearing) control animals, sug-
gesting better overall anti-tumor activity (see below for further details).
Of the organs studied, histopathological analyses revealed treat-
ment-related adverse effects in the liver, as noted, and the heart, one of
the key organs that present anthracycline-related pathologies [42,43].
The liver presented significant hydropic degeneration, suggesting pos-
sible treatment-associated toxicity (Fig. SI17) and hearts of animals
treated with Dox presented with myocardial fiber tortuosity, inter-
fibrillar edema, and abundant fibrosis as major cardiomyopathies
(Fig. 4H). Although we discovered some disperse regions presenting
minor levels of fibrosis, we observed no other major Dox-related car-
diomyopathies in animals treated with two most effective antitumor
treatments (PGA-(G-AGM)-(EMCH-Dox)LL or PGA-(G-AGM)-(Hyd-
Dox)LL).
All combination conjugates demonstrated safer in vivo therapeutic
characteristics in terms of body weight and cardiotoxicity compared to
free Dox (at even half dosage). Nevertheless, the PGA-(G-AGM)-(EMCH-
Dox)LL combination conjugate-treated animals demonstrated low
overall survival and some degree of hepatotoxicity. Of note, the PGA-
(G-AGM)-(EMCH-Dox)LL combination conjugate exhibited the lowest
Dox loading (Fig. 2A), and so, we required highly concentrated doses of
the conjugate to reach desired Dox equivalents, which increased the
final solution viscosity; a parameter with the potential to affect proper
blood distribution. Second, the larger size and heightened ability of this
combination conjugate to aggregate in solution (Fig. 2C) might promote
accumulation in other organs, as well as in the tumor. Livers from an-
imals receiving PGA-(G-AGM)-(EMCH-Dox)LL, developed even higher
hydropic degeneration (vacuolar degeneration), coinciding with organ
swelling (Fig. 4H), when compared with free Dox treatment [42] (Fig.
SI17). Chemotherapeutic drug-induced hydropic degeneration occurs
by direct and indirect toxicity mechanisms. The direct action causes
increased cell membrane injury [44] leading to cellular injury (e.g.
antineoplastic drugs such as cisplatin and Dox). The indirect action
includes the release of highly toxic and reactive free radicals [45]
causing lipid peroxidation and cell membrane damage [46] with in-
creased influx of sodium and water causing cellular swelling. Therefore,
enhanced liver toxicity and reduced overall survival might be the result
of a sum of factors, such as the possible accumulation of this conjugate
and corresponding Dox-associated toxicity in liver.
Overall, the PGA-(G-AGM)-(Hyd-Dox)LL combination conjugate
displayed the best antitumor activity and the greatest inhibition of
tumor cell proliferation without impairing safety, thereby demon-
strating the benefits of the rationally designed polymer conjugation-
based strategies.
3.4. Study of antimetastatic activity of combination conjugates and effects
over extramedullary hematopoiesis and leukemoid reaction
Lung metastasis is the most common complication in breast cancer
patients and is identified in 60–70% of all cancer patients [47]. During
primary tumor progression, cancer cells can escape from the tumor
stroma and travel through the bloodstream or lymphatic system, gen-
erating metastatic foci within the lung parenchyma or in the subpleural
region. The 4T1 orthotopic TNBC BALB/c murine model is suitable for
antimetastatic nanomedicines validation as it faithfully mimics the
human clinical scenario, including spontaneously metastatic to the lung
[10,34]. This model develops the first signs of lung metastasis around
day 3 after cells implantation although our scheduled treatment began
at day 8 (max EPR). As depicted in Fig. 5A, the PGA-(G-AGM)-(hyd-
Dox)LL combination conjugate displayed optimal antimetastatic ac-
tivity: a 90% reduction in lung metastasis when compared with non-
treated mice. The EMCH-based conjugate incorporating the lowest Dox
loading (PGA-(G-AGM)-(EMCH-Dox)LL) displayed the same antimeta-
static potential as free Dox. Further histopathological analysis con-
firmed these results (Fig. 5B); animal receiving PGA-(G-AGM)-(hyd-
Dox)LL treatment (optimal antitumor combination conjugate) also dis-
played reduced subpleural and intraparenchymatous metastatic foci
when compared with other treatments.
4T1 tumor development blocks medullar erythropoiesis and, as a
consequence, causes splenic and hepatic erythropoiesis, which pro-
motes acute splenomegaly in mice [10,48,49]. We evaluated the ca-
pacity of combination conjugates to reduce this secondary effect of
tumor progression by examining spleen weights and histopathological
features. As depicted in Fig. 5C, we observed significant decreases in
spleen weight in mice treated with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-
AGM)-(EMCH-Dox)LL, or free Dox (the most effective antitumor treat-
ments), with spleen weight in the PGA-(G-AGM)-(Hyd-Dox)HL treated
animals similar to PBS (tumor-bearing) animals. Further histopatholo-
gical analyses confirmed previous findings (Fig. 5D). We discovered
severe congestion of the red pulp and hyperplasia due to elevated re-
active hematopoiesis in the spleens of PBS control mice and the com-
bination conjugate PGA-(G-AGM)-(EMCH-Dox)HL treated mice
(Fig. 5D). Spleens from mice treated with Dox, PGA-(G-AGM)-(Hyd-
Dox)LL, or PGA-(G-AGM)-(EMCH-Dox)LL displayed a partially restored
splenic parenchyma. However, the severe leukemoid (leukocytosis)
reaction observed in the PBS treated mice developed to a lesser extent
in animals treated with Dox or with PGA-(G-AGM)-(Hyd-Dox)LL
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Fig. 5. Lung metastasis and extramedullary hematopoiesis with leuko-lymphocytosis. A) Metastasis quantification in lung by treatments group. Metastasis was
significantly decreased after the treatment with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(EMCH-Dox)LL and free Dox B) H&E Histological analysis of re-
presentative lung lobe receiving different treatments. Red arrowheads indicate metastatic nodules identified under the microscope. C) Tumor-induced splenomegaly,
demonstrating maximum weight of spleen in control animals (PBS) and those treated with PGA-(G-AGM)-(Hyd-Dox)HL. Spleens of mice treated with Dox, PGA-(G-
AGM)-(Hyd-Dox)HL or PGA-(G-AGM)-(Hyd-Dox)LL, demonstrated significant spleen weight reduction. D) Histopathological examination of spleens of mice treated
with different conjugates. Splenomegaly correlates with congested red pulp as demonstrated by H&E and CD-23 marker. 4T1 tumor development produced acute
lymphocytosis and leukocytosis (with major proportion of segmented neutrophils) as seen in the PBS-treated mice (E, F, G). Animals treated with Dox and PGA-(G-
AGM)-(Hyd-Dox)LL demonstrated a recovery to the normal levels of lymphocytes and leukocytes. Statistical significance was determined using an ANOVA t-test
(*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001). (For interpretation of the references to color in this figure legend, the reader is referred to the Web
version of this article.)
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(Fig. 5E–G), in line with the slower overall disease progression.
The reduction in metastasis at the experimental endpoint might
imply two different antimetastatic mechanisms induced by our combi-
nation conjugates. Greater anti-tumor activity (primary tumor), a re-
duction of tumor growth and tumorcell proliferation, may also inhibit
metastatic-related processes, including angiogenesis, migration, and/or
epithelial-mesenchymal transition of tumor cells. Additionally, given
the enhanced size in solution of the conjugates, the higher ability to
aggregate, and the accelerated Dox release kinetics of the low loading
combination conjugates could promote accumulation in the lungs [50],
leading to a direct effect on metastatic tumor cells. We hope that ad-
ditional experiments focused on lung accumulation will corroborate
these hypotheses.
In summary, the combination conjugates with lower Dox loading
exhibit higher antitumor and antimetastatic activity, coinciding with
higher Dox release influence by the conjugate solution conformation
and tumor stromal features.
3.5. Transcriptomic study of combination conjugates
3.5.1. GO analysis
To understand the molecular basis of the responses to the different
combination conjugates, we performed RNA-seq analysis of tumors
derived from treated animals and compared genes differentially regu-
lated between each possible pair-wise comparison (Fig. SI18). In
agreement with the above-described physiological characterization as-
says, we found that the highest number of differentially expressed
genes, compared to the PBS control group, corresponded to the PGA-(G-
AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL combination
conjugates, while the PGA-(G-AGM)-(Hyd-Dox)HL combination con-
jugate that shows no differences in tumor growth inhibition with re-
spect to PBS control had significantly lower numbers of differentially
expressed genes. We therefore concentrated our functional enrichment
analysis on PGA-(G-AGM)-(Hyd-Dox)LL, and PGA-(G-AGM)-(EMCH-
Dox)LL treatments to understand similarities and differences between
molecular responses.
GO enrichment analysis revealed the enrichment of 62 and 5 terms
in genes that were up- or down-regulated, respectively, when com-
paring (PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL)
transcriptional responses (Fig. 6A), while 11 and 10 GO terms were
enriched in up- or down-regulated genes between the two conjugates.
Upregulated processes common for PGA-(G-AGM)-(Hyd-Dox)LL and
PGA-(G-AGM)-(EMCH-Dox)LL include chemotaxis, positive regulation
of interferon gamma-mediated (IFN-γ) signaling pathway, response to
interferon alpha (IFN-α), granzyme-mediated apoptotic signaling
pathway, and autophagy of host cells, amongst others (Fig. 6B), in-
dicating that treatment induced a shared activation signature related to
inflammation, apoptosis induction and autophagy activation.
Interferon signaling pathways (IFN-α and IFN-γ) are involved in
immune response, inhibition of cell proliferation, inflammation, im-
mune surveillance and tumor suppression by inducing the transcription
of a number of IFN-stimulated genes [51]. Binding of IFN-γ and IFN-α
to their respective receptors promotes the activation of PI3K/AKT and
JAK/STAT pathways [51,52], resulting in the synthesis of several pro-
apoptotic factors, but also inhibiting the synthesis of anti-apoptotic
genes [53]. Accordingly, we detected the upregulation of the granzyme-
mediated pathway, a process that involves T-cell mediated cytotoxicity
and perforin-granzyme-dependent killing of the cell through the in-
duction of apoptosis [54], found in our enrichment results. Moreover,
we detected upregulation of autophagy, which is a different type of
active programmed cell death [55]. Interestingly, both treatments
caused a marked upregulation of T-cell chemotaxis; T-cell trafficking to
and increasing the T-cell frequency at the TME is one of the major
challenges for adoptive immunotherapy as a new strategy against
tumor development and metastasis [56].
Taken together these upregulated pathways indicate the
contribution of different cell death mechanisms, including processes
leading to apoptosis and others mediating autophagy, in both PGA-(G-
AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL treatments.
Both treatments also provoke the downregulation of processes re-
lated to cell proliferation, signaling and metastasis, blood vessel de-
velopment (angiogenesis), epithelial-mesenchymal transition (EMT),
epithelial cell proliferation involved in mammary gland duct elonga-
tion, and positive regulation of protein kinase C (Fig. 6C).
The link between angiogenesis and EMT is widely accepted, since
the same factors that drive endothelial cells toward a pro-angiogenic
phenotype may also drive epithelial cells toward a mesenchymal stem
cell (MSC) phenotype. Thus, angiogenesis can be accomplished through
endothelial sprouting or non-sprouting microvascular growth, in a si-
milar manner that endothelial cells gain invasive and migratory prop-
erties to become MSCs [57]. In this context, EMT and angiogenesis have
emerged as integral processes in the promotion of carcinogenesis
[58,59].
Moreover, genes related to epithelial cell proliferation involved in
mammary gland duct elongation also displayed a downregulation. This
GO term includes different genes, all of them playing an important role
in mammary gland organogenesis and development [60]. The mam-
mary gland epithelium passes through several cycles of proliferation
and cell death during pregnancy, lactation, and involution. However,
many of the signaling mechanisms that control the initial invasion of
the fat pad by the epithelium and regulate its continuing plasticity can
be harnessed or corrupted by tumor cells in order to support their
aberrant growth and progression towards invasion [61]. Accordingly,
we hypothesize that at least part of the anti-cancer activity of our
conjugates might be mediated by the inhibition in the proliferation of
mammary gland cells.
Additionally, the PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-
(EMCH-Dox)LL combination conjugates downregulate the protein ki-
nase C (PKC) pathway, which could imply deactivation of NFκB sig-
naling [62]. Overexpression of the factor NF-κB is frequently found in
cancer and other inflammatory diseases and a potential inhibition of
NF-κB here could be an additional anticancer effect of our combina-
torial therapy.
As mentioned, we discovered a total of 67 GO terms (5 down-
regulated terms and 62 upregulated terms) enriched in a comparison
between PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL
treated tumors. This indicates a stronger and more general effect of
PGA-(G-AGM)-(Hyd-Dox)LL when treating tumor cells compared to
PGA-(G-AGM)-(EMCH-Dox)LL. PGA-(G-AGM)-(EMCH-Dox)LL involves
fewer targeted processes, such as stem cell proliferation and epidermal
cell differentiation, indicating a role of this combination conjugate in
reducing cancer cell growth (Fig. 6D). PGA-(G-AGM)-(Hyd-Dox)LL
specifically activates general processes such as defense/immune re-
sponses, inflammation, phagocytosis, cell signaling and metastasis
(Fig. 6E), suggesting that the PGA-(G-AGM)-(Hyd-Dox)LL is more ef-
fective in provoking a general immune response that might contribute
to fight tumor progression, improve health status of the individual and
increase survival rates. In this sense, we observed higher survival rates
of mice treated with PGA-(G-AGM)-(Hyd-Dox)LL, which corroborates
this assumption.
3.5.2. Pathway analysis highlights mechanistic differences between PGA-
(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-dox)LL
We used the PaintOmics 3 tool to create a mechanistic representa-
tion of some of the processes involved in the PGA-(G-AGM)-(Hyd-
Dox)LL, and PGA-(G-AGM)-(EMCH-Dox)LL modes of action. PaintOmics
3 analysis confirmed and expanded GO enrichment results in relation to
cell survival/apoptosis (Fig. 7A) and inflammation, angiogenesis, and
metastasis (Fig. 7B), revealing additional similarities and differences
between the two conjugates.
We uncovered evidence of both conjugates inducing apoptosis
through the activation of the granzyme (GZMB) signaling pathway
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(Fig. 6B). Indeed, we found a strong upregulation of GZMB and perforin
(PRF1) for both treatments (Fig. 7A, see first two columns of gene
heatmaps); however, we also detected activation of the apoptosis ex-
trinsic pathway (Fig. 7A), which involves the activation of cell surface
death receptors (FAS, TNFR) by extracellular ligands such as FAS-L or
TNF, resulting in the cleavage or activation of caspase-8 and a signaling
cascade that culminates in cell death [63]. We note the strong upre-
gulating of all these markers for both conjugates (Fig. 7A).
We demonstrate the differences between the two conjugates in the
third column of the gene heatmaps (Fig. 7A). PGA-(G-AGM)-(Hyd-
Dox)LL exhibits consistent activation of typical pro-apoptotic markers
such as tubulin alpha 1b (TUBA1B), poly (ADP-Ribose) polymerase 1
Fig. 6. Network visualization of the statistically significant GO terms grouped by hyper-categories. A) Venn diagram comparing the GO terms up or
downregulated between PGA-(G-AGM)-(Hyd-Dox)LL- PBS; PGA-(G-AGM)-(EMCH-Dox)LL – PBS and PGA-(G-AGM)-(Hyd-Dox)LL- PGA-(G-AGM)-(EMCH-Dox)LL paired
comparisons. Red numbers: upregulated GO terms; blue numbers: downregulated genes. Networks were constructed from these results and the more relevant are
demonstrating similarities (C, E) and differences (B, D) between the two drug conjugates. Networks constructed through REVIGO web server using EBI-GOA
database. The darker the color the lower the p-value, as an indication of significance level. Nodes size indicates the frequency of the GO term in the EBI-GOA
database. Edges indicate highly similar GO terms regarding the number of genes shared. (PGA-(G-AGM)-(Hyd-Dox)LL: P-(Hyd)LL, PGA-(G-AGM)-(EMCH-Dox)LL: P-
(EMCH)LL). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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(PARP1), beta-actin (ACTB), and myeloid cell leukemia sequence 1
(MCL1) (red in gene heatmaps). However, PGA-(G-AGM)-(EMCH-
Dox)LL more frequently triggers the overexpression of cell survival and
anti-apoptotic genes, including as B-cell lymphoma 2 (BCL2), growth
arrest and DNA damage inducible alpha (GADD45A), baculoviral IAP
repeat containing 2 (BIRC2), mouse double minute 2 homolog (MDM2),
and TNF receptor associated factor 1 (TRAF1) (blue in gene heatmaps).
From these observations, we hypothesize that PGA-(G-AGM)-(Hyd-
Dox)LL treatment is not only stronger in provoking apoptosis through
upregulation of proapoptotic processes, but also reduces the expression
of genes related to cell survival and anti-apoptosis, jointly contributing
to a strong apoptotic response.
Pathway enrichment analysis also revealed stronger angiogenesis
and inflammation activities for PGA-(G-AGM)-(Hyd-Dox)LL treatment
Fig. 7. Graphical model of the transcriptional responses to PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL conjugates. The model demonstrates the
gene expression values measured by RNAseq of genes involved in A) Cell survival and apoptosis, and B) Inflammation, angiogenesis and metastasis. Each colored box
depicts the log2-fold change value between – from left to right – comparisons of PGA-(G-AGM)-(Hyd-Dox)LL and PBS, PGA-(G-AGM)-(EMCH-Dox)LL and PBS, and
PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL. Blue indicates down-regulation and red up-regulation of gene expression, respectively, for each
comparison. Green stars indicate statistically significant (p < 0.01) changes for each comparison; arrows indicate pathway relationships extracted from the KEGG
pathway database: blunt ends indicate negative regulation and arrowheads indicate positive relationships. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
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than for PGA-(G-AGM)-(EMCH-Dox)LL (Fig. 6D). Prostaglandin-en-
doperoxide synthase 2 (PTGS2), a marker of pro-angiogenesis processes
[64] that, although overexpressed for both conjugates, exhibited higher
levels for PGA-(G-AGM)-(Hyd-Dox)LL treatment (Fig. 7B). Similarly,
although inflammation was a hallmark of both treatments (Fig. 6B),
selected inflammatory biomarkers such as Interleukin (IL)1B, IL6, In-
terferon-γ and TNF-α were upregulated following PGA-(G-AGM)-(Hyd-
Dox)LL treatment compared to PGA-(G-AGM)-(EMCH-Dox)LL (Fig. 7B),
which might mediate the differential inflammatory response between
the two conjugates.
Protein tyrosine kinase 2 (PTK2) and the matrix metallopeptidases 1
and 9 (MMP1 and MMP9) displayed higher levels in PGA-(G-AGM)-
(EMCH-Dox)LL treatment (Fig. 7B), suggesting that these genes might
mediate the increased trend for heightened metastatic activity observed
in PGA-(G-AGM)-(EMCH-Dox)LL treated tumors when compared to
PGA-(G-AGM)-(Hyd-Dox)LL.
4. Conclusions
Both experimental results and transcriptional analysis indicate that
the two most effective conjugates, PGA-(G-AGM)-(Hyd-Dox)LL and
PGA-(G-AGM)-(EMCH-Dox)LL, target the TME to trigger a cascade of
molecular events that promote tumor cell death (apoptosis and autop-
hagy) and inhibit tumor-related activities, including metastasis and cell
proliferation.
However, we also highlight significant differences between the two
combination conjugates: PGA-(G-AGM)-(Hyd-Dox)LL triggers a more
intense immune response that might explain why recipient mice display
a higher survival rate. Also, PGA-(G-AGM)-(Hyd-Dox)LL leads to higher
pro-apoptotic activity, lower anti-apoptotic signals, and inhibition of
metastasis, which support the overall response to this treatment.
We have also demonstrated the relative importance of targeting the
TME for drug release and optimizing the bioavailable drug ratio in a
combination therapy, highlighting the importance of a chemical ratio-
nale for polymer-drug(s) linker design. Adequate drug release kinetics
represents a crucial parameter towards achieving an adequate safety:
efficacy ratio and may secure an adequate therapeutic window for fu-
ture treatments.
Finally, this study also demonstrates the utility of side-by-side
transcriptional analysis that serves to understand our results and pro-
mote the future design of advanced polymer-based DDS for the treat-
ment of metastatic TNBC among others.
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